Skip to content

The Effectiveness of a Bacteriophobic Coating on Urinary Catheters

A Pilot Study to Characterise the Effectiveness of a Bacteriophobic Coating in Preventing

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05719753
Acronym
PRO033CSP
Enrollment
50
Registered
2023-02-09
Start date
2020-09-15
Completion date
2021-12-20
Last updated
2023-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Tract Infections

Brief summary

To assess if a bacteriophobic coating prevents biofilm and host protein accumulation on urinary catheters and inflammatory protein release in urine following catheterization

Detailed description

The purpose of the study is to provide pilot information on the characteristics of the biofilm formed on the coated catheter compared to a standard catheter. The two objectives are; 1. to evaluate the catheter's on-label performance in customary clinical use. 2. to quantify biofilm formation on the catheter surface, and to compare it with biofilm formation on the hospitals current uncoated catheters.

Interventions

The Camstent Coated Foley Catheter is an all-silicone two-way Foley-type urinary catheter, to which a proprietary polymeric coating has been applied.

DEVICEStandard Care

Bard Catheter

Sponsors

Camstent Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. All patients undergoing colorectal resection routinely requiring a urinary catheter as part of their standard post-operative care. 2. Patients aged 18-85 years will be eligible for the study. 3. Able to give informed consent.

Exclusion criteria

1. Patients that have or recently (within 3 weeks) had a urinary catheter, or those with signs of current urinary tract infection. 2. Pregnant patients. 3. Patients with a potentially immunocompromised condition (steroids, HIV) 4. Patients who are unable to give informed consent

Design outcomes

Primary

MeasureTime frameDescription
An analytic characterisation of catheters after routine patient use, will yield estimates of the difference in biofilm density between coated and non-coated catheters.1 yearAn analytic characterisation of catheters after routine patient use, will yield estimates of the difference in biofilm density between coated and non-coated catheters.

Secondary

MeasureTime frameDescription
catheter blockage1 yearcatheter blockage
catheter associated infection1 yearcatheter associated infection
Ease of insertion and removal of the catheter since it creates a very smooth and slippery surface using the NHS staff standard clinical feedback form.1 yearEase of insertion and removal of the catheter since it creates a very smooth and slippery surface using the NHS staff standard clinical feedback form.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026